Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians
The DOI matches its Crossref record; 370 of the 370 references it cites were found in a registry or an index.
Abstract
Description: This guideline updates the 2008 American College of Physicians (ACP) recommendations on treatment of low bone density and osteoporosis to prevent fractures in men and women. This guideline is endorsed by the American Academy of Family Physicians. Methods: The ACP Clinical Guidelines Committee based these recommendations on a systematic review of randomized controlled trials; systematic reviews; large observational studies (for adverse events); and case reports (for rare events) that were published between 2 January 2005 and 3 June 2011. The review was updated to July 2016 by using a machine-learning method, and a limited update to October 2016 was done. Clinical outcomes evaluated were fractures and adverse events. This guideline focuses on the comparative benefits and risks of short- and long-term pharmacologic treatments for low bone density, including pharmaceutical prescriptions, calcium, vitamin D, and estrogen. Evidence was graded according to the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Target Audience and Patient Population: The target audience for this guideline includes all clinicians. The target patient population includes men and women with low bone density and osteoporosis. Recommendation 1: ACP recommends that clinicians offer pharmacologic treatment with alendronate, risedronate, zoledronic acid, or denosumab to reduce the risk for hip and vertebral fractures in women who have known osteoporosis. (Grade: strong recommendation; high-quality evidence). Recommendation 2: ACP recommends that clinicians treat osteoporotic women with pharmacologic therapy for 5 years. (Grade: weak recommendation; low-quality evidence). Recommendation 3: ACP recommends that clinicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fracture in men who have clinically recognized osteoporosis. (Grade: weak recommendation; low-quality evidence). Recommendation 4: ACP recommends against bone density monitoring during the 5-year pharmacologic treatment period for osteoporosis in women. (Grade: weak recommendation; low-quality evidence). Recommendation 5: ACP recommends against using menopausal estrogen therapy or menopausal estrogen plus progestogen therapy or raloxifene for the treatment of osteoporosis in women. (Grade: strong recommendation; moderate-quality evidence). Recommendation 6: ACP recommends that clinicians should make the decision whether to treat osteopenic women 65 years of age or older who are at a high risk for fracture based on a discussion of patient preferences, fracture risk profile, and benefits, harms, and costs of medications. (Grade: weak recommendation; low-quality evidence).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Affected trial reports were cited in nine effectiveness reviews and clinical guidelines (one published in Scotland, the others in the USA), for stroke,49 fracture prevention50–55 and fall and injury prevention.56”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“The updated 2017 American College of Physicians’ guidelines55 (74 citations, October 2018) includes two of the affected trial reports on 2.5 mg daily risedronate13 16 in its overview of the evidence for the use of risedronate from the AHRQ review,54 but does not discuss the specific issue of the lower dose of risedronate.”
From An investigation into the impact and implications of published papers from retracted research: systematic search of affected literature (2019) · cites this paper as [55]
In the citing paper
“Fracture risk approximately doubles with every SD T-score reduction.137,138”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [138]
Citations
Cites
9 retracted
Sato, Y., Iwamoto, J., Kanoko, T., & Satoh, K. (2005) · Cerebrovascular Diseases · doi:10.1159/000087203 · Cited by 410
RetractedWimalawansa, S. J. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00029-1 · Cited by 186
RetractedIshida, Y., & Kawai, S. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.05.019 · Cited by 132
RetractedSato, Y., Manabe, S., Kuno, H., & Oizumi, K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.1.64 · Cited by 131
Retracted(2007) · Neurology · doi:10.1212/01.wnl.0000257089.50476.92 · Cited by 90 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedSato, Y., Kanoko, T., Satoh, K., & Iwamoto, J. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.15.1737 · Cited by 69 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetracted(2003) · Neurology · doi:10.1212/01.wnl.0000078892.24356.90 · Cited by 51
RetractedSato, Y., Kuno, H., Kaji, M., Saruwatari, N., & Oizumi, K. (1999) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/00002060-199909000-00008 · Cited by 37
RetractedAnti-Fracture Efficacy of Risedronic Acid in Men: A Meta-Analysis of Randomized Controlled Trials
Zhong, Z., & Chen, J. (2009) · Clinical Drug Investigation · doi:10.2165/00044011-200929050-00007 · Cited by 30 · cited 5×
“Nakamura T, Sugimoto T, Nakano T, Kishimoto H, Ito M, Fukunaga M, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk.”
BackgroundInfluentialRetractedWriting Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Research works printed but not linked: 25
- Bonnick S, 1998, Bone, 23, S476
- 10.1210/jcem.85.2.6393 · doi:10.1210/jcem.85.2.6393 · Paper page
- 10.1185/030079903125002009 · DOI · Paper page
- McClung M, 1998, Osteoporos Int, 8, 111
- Chao M, 2013, Pak J Med Sci, 29, 1381
- Lippuner K, 2013, Osteoporosis Int, 24, S39
- Palacios S, 2013, Osteoporosis Int, 24, S299
- Papapoulos S, 2013, Osteoporosis Int, 24, S45
- 10.1359/jbmr.2003.18.1.9 · DOI · Paper page
- 10.1210/jcem.85.9.6836 · doi:10.1210/jcem.85.9.6836 · Paper page
- Adachi JD, 1996, J Rheumatol, 23, 995
- Aloia JF, 1985, J Lab Clin Med, 106, 630
- Caniggia A, 1984, Acta Vitaminol Enzymol, 6, 117
- Geusens P, 1986, Bone Miner, 1, 347
- Jensen GF, 1985, Clin Orthop Relat Res, 215
- Menczel J, 1994, Clin Orthop Relat Res, 241
- Orimo H, 1987, Bone Miner, 3, 47
- Muscoso E, 2004, Eur Rev Med Pharmacol Sci, 8, 97
- Migliore A, 2013, Eur Rev Med Pharmacol Sci, 17, 658
- Almăşan HA, 2011, Rom J Morphol Embryol, 52, 1233
- 10.1056/nejmoa011807 · DOI · Paper page
- Krohn K, 2014, Osteoporosis Int, 25, S61, 10.1007/s00198-013-2525-0 · DOI
- 10.1210/jcem.87.3.8325 · doi:10.1210/jcem.87.3.8325 · Paper page
- Zheng S, 2003, Chin Med J (Engl), 116, 1127
- Liu JL, 2004, Chin Med J (Engl), 117, 1029
Cited by
Items 201–300 of 741
Jin, Z., Chen, J., Shu, B., Xiao, Y., & Tang, D. (2019) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-019-2851-2 · Cited by 23
on behalf of other members of the Technical Working Group, Gimigliano, F., Liguori, S., Moretti, A., Toro, G., Rauch, A., Négrini, S., Curci, C., Patrini, M., Peschi, L., et al. (2020) · Journal of Orthopaedics and Traumatology · doi:10.1186/s10195-020-00560-w · Cited by 23
Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway
Hoff, M., Skurtveit, S. O., Meyer, H. E., Langhammer, A., Søgaard, A. J., Syversen, U., Skovlund, E., Abrahamsen, B., Forsmo, S., & Schei, B. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4560-3 · Cited by 23
“Teriparatide has also been found to reduce subsequent fracture in women with osteopenia [32, 36-38].”
BackgroundMori, T., Crandall, C. J., Fujii, T., & Ganz, D. A. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00956-z · Cited by 22
“There also does not appear to be a consensus regarding when patients should undergo a DXA scan after the initiation of osteoporosis treatments [10, 12, 20]; we charged the costs of a DXA scan at the end of the third and the sixth year.”
BackgroundMannino, F., Imbesi, C., Irrera, N., Pallio, G., Squadrito, F., & Bitto, A. (2023) · BioFactors · doi:10.1002/biof.2008 · Cited by 22
Fouad-Elhady, E. A., Aglan, H. A., Hassan, R. E., Ahmed, H. H., & Sabry, G. M. (2020) · Heliyon · doi:10.1016/j.heliyon.2020.e03341 · Cited by 22
“Despite these drugs show the desirable therapeutic effectiveness, the semipermanent use of them will bring about many adverse events in the long run, like gastrointestinal problems, typical femoral subtrochanteric fractures, and some drug-specific infections [10, 11].”
BackgroundAfter the initial fracture in postmenopausal women, where do subsequent fractures occur?
Crandall, C. J., Hunt, R., LaCroix, A. Z., Robbins, J. A., Wactawski‐Wende, J., Johnson, K., Sattari, M., Stone, K. L., Weitlauf, J. C., Gure, T. R., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100826 · Cited by 22
“Some clinical guidelines consider previous “fragility fracture” to be diagnostic of osteoporosis [20,21].”
BackgroundBastounis, A., Langley, T. E., Davis, S., Paskins, Z., Gittoes, N. J. L., Leonardi‐Bee, J., & Sahota, O. (2022) · JBMR Plus · doi:10.1002/jbm4.10620 · Cited by 22
“the light of adverse events associated with the use of bisphosphonates.((2)) There is a need, therefore, to undertake a compar-”
BackgroundSun, J., Liu, Q., He, H., Jiang, L., Lee, K., Li, D. M., & Ma, J. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101350 · Cited by 22
Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition
Conley, R. B., Adib, G., Adler, R. A., Åkesson, K., Alexander, I. M., Amenta, K. C., Blank, R. D., Brox, W. T., Carmody, E. E., Chapman‐Novakofski, K., et al. (2020) · Journal of Orthopaedic Trauma · doi:10.1097/bot.0000000000001743 · Cited by 21
“Alendronate and risedronate are oral bisphosphonates, which function as antiresorptives and have been shown to reduce the risk of hip, vertebral, and nonvertebral fractures in postmenopausal osteoporotic women.((5,19,20)) They also are generally well tolerated, easier for patients to self-administer compared with an i…”
BackgroundInfluentialU.S. Montmorency Tart Cherry Juice Decreases Bone Resorption in Women Aged 65–80 Years
Dodier, T., Anderson, K. L., Bothwell, J. D., Hermann, J., Lucas, E. A., & Smith, B. J. (2021) · Nutrients · doi:10.3390/nu13020544 · Cited by 21
Stimulant use and bone health in US children and adolescents: analysis of the NHANES data
Fu, Y., Wang, G., Liu, J., Li, M., Dong, M., Zhang, C., Xu, R., & Liu, X. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-021-04356-w · Cited by 21
“3 billion dollars in costs per year by 2025 [2, 3].”
BackgroundBone turnover markers to monitor oral bisphosphonate therapy
ASHCHERKIN, N., Patel, A. A., Algeciras‐Schimnich, A., & Doshi, K. B. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22002 · Cited by 21
Leder, B. Z. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3359 · Cited by 21
Cai, W., Sun, B., Song, C., Liu, F., Wu, Z., & Liu, Z. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-03943-8 · Cited by 20
Zhang, R., Yan, K. H., Chen, H., Zhang, Y., Li, G.-J., Chen, X., Ge, L., Cheng, F., Chen, Z., & Yao, X. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1091083 · Cited by 20
“Osteoporosis (OP) has become a nonnegligible disease affecting the quality of life of the elderly (Qaseem et al., 2017).”
BackgroundEfficacy and safety of tai chi exercise on bone health: An umbrella review
Li, J., Guo, J., Wang, X., Zhang, X., Zhang, Y., Bu, M., Yao, X., & Yanfen, S. H. E. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06830-7 · Cited by 20
“Pharmacological treatments for promoting bone health include bisphosphonates, oestrogen, and selective oestrogen receptor modulators, which can prevent bone resorption (Qaseem et al., 2017; [12].”
BackgroundYang, J., Guo, X., Cui, Z., Guo, H., & Dong, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431676 · Cited by 21
Li, M., Yu, B., Yang, H., He, H., Li, N., Lv, A., Zhou, X., & Gao, R. (2024) · Journal of Health Population and Nutrition · doi:10.1186/s41043-024-00690-5 · Cited by 20
Zheng, H., Liu, X., Liang, X., Guo, S., Qin, B., Liu, E., & Duan, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.139852 · Cited by 20
Majumdar, S. R., Lier, D. A., McAlister, F. A., Johnson, J. A., Rowe, B. H., & Beaupré, L. A. (2019) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3699 · Cited by 20
“We also note that our trial population (and subsequent model assumptions) were patients who were osteoporosistreatment–naive at the time of fracture because one of our exclusion criteria was already being treated with a bisphosphonate, and that similar to other trials, most of the data demonstrating the antifracture b…”
ResultIs ankle fracture related to low bone mineral density and subsequent fracture? A systematic review
Therdyothin, A., Phiphopthatsanee, N., Wajanavisit, W., Woratanarat, P., Laohajaroensombat, S., & Tawonsawatruk, T. (2020) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2020.08.003 · Cited by 20
“Osteoporosis is a major cause of disability worldwide [1,2].”
BackgroundWu, J., Cai, P., Lu, Z., Zhang, Z., He, X., Zhu, B., Li, Z., & Zhao, J. (2020) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-020-01965-3 · Cited by 20
Sato, A. Y., Pellegrini, G., Cregor, M. D., McAndrews, K., Choi, R. B., Maiz, M., Johnson, O., McCabe, L. D., McCabe, G. P., Ferruzzi, M. G., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4231 · Cited by 20
Zileli, M., Fornari, M., COSTA, F., Anania, C. D., PARTHIBAN, J., & SHARIF, S. (2022) · Journal of Neurosurgical Sciences · doi:10.23736/s0390-5616.22.05643-0 · Cited by 20
Sun, Q., Zhang, B., Zhu, W., Wei, W., Ma, J., & Tay, F. R. (2019) · Journal of Dentistry · doi:10.1016/j.jdent.2019.01.015 · Cited by 20
Tang, Y., Yi, Q., Wang, S., Xia, Y., & Geng, B. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-16162-w · Cited by 19
“According to the clinical guideline (Qaseem et al. 2017), previous study (Sànchez-Riera et al.”
MethodResultHossen, M. S., Islam, M. T., Hoque, A., Alenezi, A. M., Kirawanich, P., Baharuddin, M. H., Faouri, Y. S., & Rahman, M. A. (2024) · IEEE Access · doi:10.1109/access.2024.3487858 · Cited by 19
CROMER, S. J., D’Silva, K. M., Yu, E. W.-Y., Landon, J. E., Desai, R. J., & Kim, S. C. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-06938-8 · Cited by 19
Li, H., Xiao, W., He, Y., Wen, Z., Cheng, S., Zhang, Y., & Li, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.766020 · Cited by 19
“However, the current treatment protocols for OP have some issues, such as a long treatment cycle time and poor patient compliance (Qaseem et al., 2017; Estell and Rosen, 2021).”
BackgroundKadri, A., Binkley, N., Daffner, S. D., & Anderson, P. A. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.00012 · Cited by 19
Long waiting time before tooth extraction may increase delayed wound healing in elderly Japanese
Kamimura, M., Taguchi, A., Komatsu, M., Koiwai, H., Ashizawa, R., Ichinose, A., Takahara, K., Uchiyama, S., & Kato, H. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4775-3 · Cited by 19
Kline, G. A., Lix, L. M., & Leslie, W. D. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4333 · Cited by 19
“occurring on treatment, some guidelines have argued that a monitoring DXA-BMD should not be performed at all.((11)) This”
BackgroundCheng, B.-R., Wu, R.-Y., Gao, Q.-Y., Jiang, K.-X., Li, S.-S., Qi, S.-H., Yuan, M.-Y., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.870277 · Cited by 18
When and How to Evaluate Vitamin D Status? A Viewpoint from the Belgian Bone Club
Lapauw, B., Laurent, M. R., Rozenberg, S., Body, J., Bruyère, O., Gielen, E., Goemaere, S., Iconaru, L., & Cavalier, E. (2024) · Nutrients · doi:10.3390/nu16152388 · Cited by 18
“Most professional societies recommend vitamin D supplementation for patients at a high risk of fracture and/or those receiving pharmacological osteoporosis treatments independent of baseline vitamin D status to avoid incident vitamin D deficiency and reduce the risk of hypocalcaemia [3,88–95].”
BackgroundRisk of complete atypical femur fracture with Oral bisphosphonate exposure beyond three years
Lo, J. C.-M., Neugebauer, R. S., Ettinger, B. B., Chandra, M., Hui, R. L., Ott, S. M., Grimsrud, C. D., & Izano, M. A. (2020) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-020-03672-w · Cited by 18
Lu, H., Lei, X. J., Zhao, H., Elting, L. S., Siricilla, M., Ursani, M. A., Giordano, S. H., & Suarez-Almazor, M. E. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4250 · Cited by 18
“3) 6332 (41) 9094 (59) Exemestane only 827 (3.”
Hormone therapy for postmenopausal osteoporosis management
Jiang, X., & Kagan, R. (2021) · Climacteric · doi:10.1080/13697137.2021.1957818 · Cited by 18
Transcription Factor KLF7 Promotes Osteoclast Differentiation by Suppressing HO-1
Chen, C., Hu, F., Miao, S., Sun, L., Jiao, Y.-J., Xu, M., Huang, X., Yang, Y., & Zhou, R. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.798433 · Cited by 18
“The clinical treatment of osteoporosis mainly includes calcium and vitamin-based nutrients, estrogen receptor modulators, disphosphonates, and anti-RANKL drugs, etc. (Qaseem et al., 2017).”
BackgroundClinical risk factor status in patients with vertebral fracture but normal bone mineral density
Kadri, A., Binkley, N., Daffner, S. D., & Anderson, P. A. (2022) · The Spine Journal · doi:10.1016/j.spinee.2022.05.019 · Cited by 18
Liu, K., Tan, G., Sun, W., Lü, Q., Tang, J., & Yu, D. (2022) · Archives of Orthopaedic and Trauma Surgery · doi:10.1007/s00402-022-04557-4 · Cited by 18
“Thus, ZOL is recommended by the American College of Physicians for reducing the risk for vertebral fractures in women and men who have known osteoporosis [29].”
BackgroundControversies in Osteoporosis Treatment of Nursing Home Residents
Niznik, J. D., Gilliam, M., Colon-Emeric, C. S., Thorpe, C. T., Lund, J. L., Berry, S. D., & Hanson, L. C. (2022) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2022.09.013 · Cited by 18
Zhou, X., Sun, S., Chen, Y., Liu, C., Li, D., Cheng, Q., Cheng, Q., Li, Y., Xu, K., & Ta, D. (2023) · Ultrasonics · doi:10.1016/j.ultras.2023.106973 · Cited by 18
Sahni, P., & Nieves, J. W. (2019) · HSS Journal® The Musculoskeletal Journal of Hospital for Special Surgery · doi:10.1007/s11420-019-09686-y · Cited by 17
Coyle, D. (2019) · MDM Policy & Practice · doi:10.1177/2381468318818843 · Cited by 17
Balancing Altered Calcium Metabolism with Bone Health in Sarcoidosis
Zhou, Y. F., & Lower, E. E. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1713009 · Cited by 17
Ng, J. Y., Hilal, A., & Maini, I. (2021) · Integrative Medicine Research · doi:10.1016/j.imr.2021.100803 · Cited by 17
Liapaki, A., Chen, Y., Hadad, H., Guastaldi, F. P. S., & August, M. A. (2022) · Journal of Stomatology Oral and Maxillofacial Surgery · doi:10.1016/j.jormas.2022.06.023 · Cited by 17
Lin, X., Guo, H., Lian, Y., Kou, J., Wang, G., Chen, Y., Wang, J., Han, X., Jiang, M., & Yang, Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.875678 · Cited by 17
High Rates of Imminent Subsequent Fracture After Femoral Neck Fracture in the Elderly
Bogoch, E. R., Marcano-Fernández, F. A., Schemitsch, E. H., Zhou, Q. X., Bzovsky, S., Bhandari, M., Schneider, P., Swiontkowski, M. F., Sprague, S., the FAITH Investigators, et al. (2022) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.22.00088 · Cited by 17
Yu, Z., Wu, Y., Zhang, R., Li, Y., Zang, S., & Liu, J. (2022) · Endocrine Connections · doi:10.1530/ec-22-0174 · Cited by 17
Leslie, W. D., Hans, D. B., & Silva, B. C. C. (2023) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2023.01.001 · Cited by 17
Isoflavones and bone health in perimenopausal and postmenopausal women
Lambert, M. N. T., & Jeppesen, P. B. (2018) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000513 · Cited by 17
Crosstalk between kidney and bones: New perspective for modulating osteoporosis
Duan, Y., Zhao, L., Lu, Y., Li, J., & Li, S. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102776 · Cited by 16
Wang, Z., Zhuang, C., Chen, W., Li, Z., Li, J., Lin, H., & Dong, J. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s333207 · Cited by 16
Zhou, L., Zheng, J., Chen, J., Chen, M., & Dong, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/2098820 · Cited by 16
“Estrogen therapy, menopausal estrogen plus progestogen therapy, or raloxifene is suitable for postmenopausal women [10].”
BackgroundA narrative review of the pharmaceutical management of osteoporosis
Patel, D., Gorrell, C., Norris, J., & Liu, J. (2023) · Annals of Joint · doi:10.21037/aoj-23-2 · Cited by 16
“The American College of Physicians (ACP) strongly recommends treatment with alendronate, risedronate, zoledronate, or denosumab for women with known osteoporosis to reduce the risk for hip and vertebral fractures (67).”
Paul, T., Cherian, K. E., Kapoor, N., Asha, H., & Thomas, N. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_77_18 · Cited by 16
SOLID’OS Working Group, Beauvais, C., Poivret, D., Lespessailles, É., Thevenot, C., Aubraye, D., Ziegler, L. E., Béranger, M., Filaire, E., Gendarme, S., et al. (2019) · Calcified Tissue International · doi:10.1007/s00223-019-00607-z · Cited by 16
6′-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding
Powell, K. M., Brown, A. P., Skaggs, C., Pulliam, A. N., Berman, A. G., Deosthale, P. J., Plotkin, L. I., Allen, M. R., Williams, D. R., & Wallace, J. M. (2020) · Bone Reports · doi:10.1016/j.bonr.2020.100246 · Cited by 16
YBX1 alleviates ferroptosis in osteoporosis via the ATF4/FSP1 axis in an m5C manner
Tong, L., Chen, Y., Gao, Y., Gao, X., & Hao, Y. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-024-05119-7 · Cited by 15
Jiang, B., Feng, C., Li, C., Tu, C., & Li, Z. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.961471 · Cited by 15
Drug-induced osteoporosis and mechanisms of bone tissue regeneration through trace elements
da Costa, N. D. S., Lima, L. S., Galiciolli, M. E. A., Ribeiro, D. H. F., Ribeiro, M. M., Garica, G. D. P. J., Marçal, I. S., da Silva, J. F., Pereira, M. E., Oliveira, C. S., et al. (2024) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2024.127446 · Cited by 15
Avdeeva, E. Y., Porokhova, E. D., Хлусов, И. А., Rybalova, T. V., Shults, E. E., Litvinova, L. S., Shupletsova, V. V., Хазиахматова, О. Г., Суходоло, И. В., & Белоусов, М. В. (2021) · Pharmaceuticals · doi:10.3390/ph14060579 · Cited by 15
Prediction of risk of osteoporosis after gastrectomy for gastric cancer
Park, K. B., Jeon, C. H., Lee, H. H., Chin, H.-M., & Song, K. Y. (2021) · BJS Open · doi:10.1093/bjsopen/zrab123 · Cited by 15
Goeree, R. A., Burke, N., Jobin, M., Brown, J. P., Lawrence, D., Stollenwerk, B., Willems, D., & Johnson, B. (2022) · Archives of Osteoporosis · doi:10.1007/s11657-022-01106-9 · Cited by 15
“Patients in all arms were assumed to be treated for a total of 5 years; a commonly recommended duration for pharmacological osteoporosis therapy [25].”
BackgroundTong, Y. Y. F., Holmes, S., & Sefton, A. K. (2022) · ANZ Journal of Surgery · doi:10.1111/ans.17792 · Cited by 15
“This echoes an international trend supporting prompt initiation of antiresorptive therapy in highrisk individuals, such as people who have recently suffered a low-trauma fragility fracture.(7,8) Bisphosphonates such as zoledronic acid, risedronate and alendronate are commonly used for secondary prevention of osteoporo…”
BackgroundAssociation of bisphosphonates with diabetes risk and glycemic control: a meta-analysis
Chen, P.-W., Su, H., Tu, Y., Wu, C., Yeh, J., Chen, L., Peng, C. C., Loh, C., Huang, H., & Lin, S. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06616-3 · Cited by 15
“Bisphosphonate (BP), a bone resorption inhibitor, is the first-line anti-osteoporosis drug widely used worldwide [12].”
BackgroundWei, F., Gao, Q.-Y., Zhu, K.-L., Wei, H., Du, M., Yang, F., Gao, H.-R., Li, T., Qian, J., & Zhou, C.-P. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e11880 · Cited by 15
Lu, X., Wei, J., Liu, Y., & Lu, Y. (2023) · Archives of Osteoporosis · doi:10.1007/s11657-023-01317-8 · Cited by 15
“Most of the current osteoporosis studies are on women, especially postmenopausal women, and very few studies are on men [7].”
Jeon, I., Park, S. B., Moon, B. J., Choi, M., Kuh, S. U., & Kim, J. (2024) · Neurospine · doi:10.14245/ns.2347256.628 · Cited by 15
Lewiecki, E. M., Binkley, N., & Bilezikian, J. P. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13707 · Cited by 15
Berry, S. D., Dufour, A. B., Travison, T. G., Zhu, H., Yehoshua, A., Barron, R., Recknor, C. P., & Samelson, E. J. (2018) · Archives of Osteoporosis · doi:10.1007/s11657-018-0528-3 · Cited by 15
Spinelli, M. A., Glidden, D. V., Anderson, P. L., Gandhi, M., McMahan, V., Defechereux, P. A., Schechter, M., Veloso, V. G., Chariyalertsak, S., Guanira, J. V., et al. (2019) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2018.0297 · Cited by 15
The Therapeutic Role of Genistein in Perimenopausal and Postmenopausal Women.
Nestor, M. S., Bhupalam, V., Awad, N., & Hetzel, J. D. (2024) · PubMed Central · Cited by 14
Review of Osteoporotic Fractures: Occurrence, Prevention, and Consequences
Elias, N., Ribeiro, J. E. G., Campinho, L. A., Reis, C., Elias, L. A. M. S., & Labronici, P. J. (2025) · Revista Brasileira de Ortopedia · doi:10.1055/s-0044-1789220 · Cited by 14
Mechanisms of SIRT3 Regulation of Aging and Aging-Related Diseases and Advances in Drug Therapy
Yang, J., Lu, Y., Zhao, Y. C., & Wang, X. (2025) · Gerontology · doi:10.1159/000547549 · Cited by 14
The role of vitamin D on rotator cuff tear with osteoporosis
Liu, G., Li, W., Zhang, L., Chao Hui, Z. H. O. U., & Cong, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1017835 · Cited by 14
Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly
Sáez-López, P., Etxebarría-Foronda, Í., Lampré, M. P. M., García, N. A., & Hernández, N. S. (2018) · Revista Española de Geriatría y Gerontología · doi:10.1016/j.regg.2018.11.007 · Cited by 14
Lyu, H., Yoshida, K., Tedeschi, S. K., Zhao, S. S., Xu, C. Q., Nigwekar, S. U., Leder, B. Z., & Solomon, D. H. (2019) · Osteoporosis International · doi:10.1007/s00198-019-04847-5 · Cited by 14
Role of Bisphosphonate Therapy in Patients with Osteopenia: A Systemic Review
Iqbal, S. M., Qamar, I., Zhi, C., Nida, A., & Aslam, H. M. (2019) · Cureus · doi:10.7759/cureus.4146 · Cited by 14
Lewiecki, E. M., Bilezikian, J. P., Kagan, R., Krakow, D., McClung, M. R., Miller, P. D., Rush, E. T., Shuhart, C., Watts, N. B., & Yu, E. W.-Y. (2019) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2019.09.006 · Cited by 14
Zhou, H., Li, H., Xu, W., Yan-Yi, W. E. I., Yu, R., Wang, W., & Chen, Y. (2021) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(21)60003-1 · Cited by 14
Huang, X., Chen, B., Thabane, L., Adachi, J. D., & Li, G. (2021) · Osteoporosis International · doi:10.1007/s00198-021-05865-y · Cited by 14
Bastounis, A., Langley, T. E., Davis, S., Paskins, Z., Gittoes, N. J. L., Leonardi‐Bee, J., & Sahota, O. (2022) · Osteoporosis International · doi:10.1007/s00198-022-06350-w · Cited by 14
“One trial provided data on the comparison of PLB versus ZOL, with PLB participants being more compliant and this effect was statistically significant [3].”
BackgroundInfluentialManagement of bone and metabolic effects of androgen deprivation therapy
Russell, N., & Grossmann, M. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.10.007 · Cited by 14
Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women
Forciea, M. A., McLean, R. M., & Qaseem, A. (2017) · Annals of Internal Medicine · doi:10.7326/l17-0490 · Cited by 14
Self-citationPathophysiology and Therapeutic Management of Bone Loss in Patients with Critical Illness
Kim, T. J., & Kim, H. (2023) · Pharmaceuticals · doi:10.3390/ph16121718 · Cited by 13
Wu, X., Jin, X., Xu, W., She, C., Li, L., & Mao, Y. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1403450 · Cited by 13
Carugo, S., Vescini, F., Giusti, A., Mauro, G. L., Tafaro, L., Festuccia, F., Muraca, L., Mené, P., & Rossini, M. (2024) · Archives of Osteoporosis · doi:10.1007/s11657-024-01451-x · Cited by 14
Jiang, X. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001124 · Cited by 13
Liu, T., & Guo, J. (2020) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2020.104713 · Cited by 13
Nowak, B., Matuszewska, A., Tomanik, M., Filipiak, J., Kucharska, A. Z., Piórecki, N., Jędrzejuk, D., Zduniak, K., Trocha, M., Bolanowski, M., et al. (2020) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/127683 · Cited by 13
Chen, J., Ruan, H., Liu, Y., Bao, J.-M., Xu, H., Yao, M., Cui, X., Liang, Q., & Wang, Y. (2018) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0000000000001285 · Cited by 13
Long-Term Drug Therapy and Drug Holidays for Osteoporosis Fracture Prevention: A Systematic Review
Fink, H. A., MacDonald, R. H., Forte, M. L., Rosebush, C. E., Ensrud, K. E., Schousboe, J. T., Nelson, V. A., Ullman, K. E., Butler, M., Olson, C. M., et al. (2019) · doi:10.23970/ahrqepccer218 · Cited by 13
Gates, M., Pillay, J., Thériault, G., Limburg, H., Grad, R. M., Klarenbach, S. W., Korownyk, C. S., Reynolds, D. L., Riva, J. J., Thombs, B. D., et al. (2019) · Systematic Reviews · doi:10.1186/s13643-019-1094-5 · Cited by 13
Hsu, C., Chen, H., Chen, H.-J., Chou, M.-Y., Wang, Y., Hsu, Y., Liang, C., & Chu, C. (2020) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2020.104021 · Cited by 13
Kim, J., Jang, S. B., Kim, S. W., Oh, J.-K., & Kim, T.-H. (2018) · The Spine Journal · doi:10.1016/j.spinee.2018.08.014 · Cited by 13
Jandaghian, Z., Abdinian, M., & Mortazavi, M. (2019) · Indian Journal of Dental Research · doi:10.4103/ijdr.ijdr_175_18 · Cited by 13
Lee, C., Huang, T.-J., Wu, M., Li, Y., & Lee, K. (2019) · BioMed Research International · doi:10.1155/2019/4714279 · Cited by 13
Metadata
- Authors
- Qaseem, A., Forciea, M. A., McLean, R. M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians*
- Affiliations
- Yale University (US)
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2017-06-06
- Volume
- 166
- Issue
- 11
- Pages
- 818-839
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2614075773
- Cited by
- 676
- References
- 368
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 65 · 2023: 85 · 2022: 82 · 2021: 81 · 2020: 95 · 2019: 75 · 2018: 70 · 2017: 35
- FWCI
- 83.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- osteoporosis, osteopenia, fracture prevention, pharmacotherapy, bisphosphonates, denosumab, zoledronic acid, risedronate, alendronate, hormone replacement therapy, raloxifene, calcium and vitamin D supplementation, treatment duration, hip fracture
- MeSH terms
- Denosumab, Bone Diseases, Metabolic, Calcium, Dietary, Diphosphonates, Female, Humans, Male, Osteoporosis, Risk Factors, Vitamin D, Exercise, Osteoporosis, Postmenopausal, Estrogen Replacement Therapy, Teriparatide, Raloxifene Hydrochloride, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.